Shamima Saloojee1, Jonathan K Burns1, Ayesha A Motala2. 1. Department of Psychiatry, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. 2. Department of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Abstract
BACKGROUND: To determine the prevalence and incidence of metabolic syndrome in individuals with a first episode of severe mental illness from South Africa. METHODS: Antipsychotic naïve study subjects with a first episode of severe mental illness and control subjects were recruited at baseline for a prospective study. Individuals without metabolic syndrome at baseline were followed up for 12 months after antipsychotic medication was initiated. Metabolic syndrome was determined at baseline and at the 12-month follow-up using the Joint Interim Statement criteria. RESULTS: At baseline, the 67 study (M:F; 48:19) and 67 control subjects (M:F; 48:19) had a mean age of 22.8 (±3.7) and 23.3 (±2.6) years (P = .4), respectively. The majority were of black African ethnicity (97%) and 82% were diagnosed with schizophrenia. There was no difference in the prevalence of metabolic syndrome (4.5%) or any of the individual components between the study and control group prior to the initiation of antipsychotics. Of the 64 study subjects without metabolic syndrome at baseline, only 36 (M:F; 25:11) completed the 12-month follow-up (response rate 56.3%) and 2 subjects developed metabolic syndrome .The incidence of metabolic syndrome was 5.5% with a significant increase in the elevated waist circumference criterion after 1 year of antipsychotic treatment (P = .02). CONCLUSIONS: There was a low prevalence and incidence of metabolic syndrome in this group of patients with a first episode of severe mental illness.
BACKGROUND: To determine the prevalence and incidence of metabolic syndrome in individuals with a first episode of severe mental illness from South Africa. METHODS: Antipsychotic naïve study subjects with a first episode of severe mental illness and control subjects were recruited at baseline for a prospective study. Individuals without metabolic syndrome at baseline were followed up for 12 months after antipsychotic medication was initiated. Metabolic syndrome was determined at baseline and at the 12-month follow-up using the Joint Interim Statement criteria. RESULTS: At baseline, the 67 study (M:F; 48:19) and 67 control subjects (M:F; 48:19) had a mean age of 22.8 (±3.7) and 23.3 (±2.6) years (P = .4), respectively. The majority were of black African ethnicity (97%) and 82% were diagnosed with schizophrenia. There was no difference in the prevalence of metabolic syndrome (4.5%) or any of the individual components between the study and control group prior to the initiation of antipsychotics. Of the 64 study subjects without metabolic syndrome at baseline, only 36 (M:F; 25:11) completed the 12-month follow-up (response rate 56.3%) and 2 subjects developed metabolic syndrome .The incidence of metabolic syndrome was 5.5% with a significant increase in the elevated waist circumference criterion after 1 year of antipsychotic treatment (P = .02). CONCLUSIONS: There was a low prevalence and incidence of metabolic syndrome in this group of patients with a first episode of severe mental illness.
Authors: Stefanie Malan-Müller; Sanja Kilian; Leigh L van den Heuvel; Soraya Bardien; Laila Asmal; Louise Warnich; Robin A Emsley; Sîan M J Hemmings; Soraya Seedat Journal: Schizophr Res Date: 2015-11-25 Impact factor: 4.939
Authors: B Chiliza; L Asmal; P Oosthuizen; E van Niekerk; R Erasmus; M Kidd; A Malhotra; R Emsley Journal: Eur Psychiatry Date: 2015-01-07 Impact factor: 5.361
Authors: Marc De Hert; Vincent Schreurs; Kim Sweers; Dominique Van Eyck; Linda Hanssens; Sebastjan Sinko; Martien Wampers; Andre Scheen; Joseph Peuskens; Ruud van Winkel Journal: Schizophr Res Date: 2008-03-04 Impact factor: 4.939